Novartis’s JAK Inhibitor Fails In COVID, Raising Questions On Lilly Prospects

Adds To Puzzle Over JAK Inhibitors

 
• By Andrew McConaghie

The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.

Covid19_Hospital_Room
The search goes on for therapies which can prevent deaths in people with severe COVID-19.

More from Business

More from Scrip